The company has not filed an annual or quarterly report since its FY2024 10-K, filed Mar 4, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2025.
10-K for FY2024, filed Mar 4, 2025
The sections below describe the company as of the FY2024 annual report.
Sells spinal cord stimulation systems and minimally invasive sacroiliac-joint fusion devices for physicians treating chronic pain.
10-K for FY2024, filed Mar 4, 2025We are a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for…View ↗
We developed and commercialized our HFX™ SCS platform, which includes the Senza® SCS system, an evidence-based neuromodulation system for…View ↗
In November 2023, we acquired Vyrsa™ Technologies ("Vyrsa"), which developed and manufactured a portfolio of SI joint fusion devices, to…View ↗
We maintain a sales organization as our main channel to communicate with our customers. Our sales representatives target physician…View ↗
Hospitals and medical facilities pay for devices delivered during implantation after the procedure is completed and authorized; customers ordering products in advance, including distributors, owe payment regardless of use. Invoices are generally due 30 to 60 days later.
10-K for FY2024, filed Mar 4, 2025
$408.5M
10-K for FY2024, filed Mar 4, 2025
$408.5M ↗
Sales representatives work with physicians involved in SCS treatment decisions; products are delivered to hospitals and medical facilities, and some are sold through distributors.
10-K for FY2024, filed Mar 4, 2025We maintain a sales organization as our main channel to communicate with our customers. Our sales representatives target physician…View ↗
For a majority of sales, where the Company’s sales representative delivers its product at the point of implantation at hospitals or medical…View ↗
For the remaining sales, which are sent from the Company’s distribution centers directly to hospitals and medical facilities, as well as…View ↗
No. It lost $113.4M in FY2024.
8-K, filed Apr 3, 2025
On April 3, 2025, the Merger was completed. Upon the consummation of the Merger, Nevro became a wholly owned subsidiary of Globus.View ↗
Grew. Revenue grew 13% in 4 years, from $362M in FY2020 to $408.5M in FY2024, about 3% a year.
Added SI-joint fusion devices
The older report describes the Senza spinal cord stimulation system; the latest report also includes minimally invasive SI-joint treatments through fusion devices acquired with Vyrsa.
10-K for FY2021, filed Feb 23, 2022 10-K for FY2024, filed Mar 4, 2025OverviewView ↗
Competes with Medtronic, Boston Scientific, Abbott Laboratories, Saluda, Biotronik, PainTeq, and SI Bone
10-K for FY2024, filed Mar 4, 2025We compete in the SCS market for chronic pain. We also compete with spine surgeries, in particular re-operations. Currently, our major…View ↗
Loading...